<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ineffective haemopoiesis leading to cytopenia presents the major clinical management problem for patients with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Preliminary studies have demonstrated that the synthetic aminothiol <z:chebi fb="0" ids="2636">Amifostine</z:chebi> stimulates multilineage haemopoiesis both in vitro and in vivo in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We have treated 12 patients with an uninterrupted 8-week schedule of thrice-weekly intravenous <z:chebi fb="0" ids="2636">Amifostine</z:chebi> with a starting dose of 300 mg/m2 escalating to 450 mg/m2 in non-responders </plain></SENT>
<SENT sid="3" pm="."><plain>No patients satisfied response criteria on study but two patients showed minor responses </plain></SENT>
<SENT sid="4" pm="."><plain>We conclude that therapeutic response to <z:chebi fb="0" ids="2636">Amifostine</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> may be schedule dependent </plain></SENT>
</text></document>